SciFi Futures
← Capabilities
Biotech & Medicine/Component technology

In vitro gametogenesis

Turning ordinary body cells into functional eggs or sperm in culture, giving an essentially unlimited supply of gametes from one donor.

State of the art

Conception reported the first stem-cell-derived human early-egg cells within lab-grown follicle structures (June 2026); the alternative nuclear-transfer route produced 82 human oocytes of which under 9 percent reached blastocyst (2025); mouse IVG produced healthy, fertile pups (Hayashi, 2016).

What’s blocking it
  • Human oocyte maturation needs months of follicle growth that culture cannot yet sustain
  • Meiotic recombination and chromosome segregation are error-prone outside the ovary, giving aneuploidy
  • Imprinting marks are set during germ-cell development and are mis-set in vitro, with no safety assay short of a live birth

Who’s working on it

  • Reported the first stem-cell-derived human primary oocytes inside entirely iPSC-derived follicle structures, from a blood draw (June 2026)

  • Katsuhiko HayashiResearcher
    Osaka University

    Produced healthy fertile mouse pups from iPSC-derived eggs (2016), the only complete mammalian IVG demonstration, and collaborates with Conception

  • ASHBi, Kyoto University

    Generated human oogonia from iPSCs (Science, 2018) and reconstituted human germline epigenetic reprogramming in vitro (Nature, 2024), defining the steps the field has to reproduce

  • Gameto ↗Startup

    Its iPSC-derived ovarian support cell product Fertilo produced the first live birth from stem-cell-assisted egg maturation (December 2024) and is in Phase 3 after a $44M Series C in August 2025

  • OvelleStartup

    Boston company founded in 2024 working on human in vitro oogenesis via meiotic oogonia in ovarian organoids; disclosed about $7M of a $9.2M offering in 2026

  • Shoukhrat MitalipovResearcher
    Oregon Health & Science University

    Pursues the nuclear-transfer alternative to stem-cell IVG; his team produced 82 human oocytes of which under 9 percent reached blastocyst (2025)

What to invest in

KindInvestmentScale
researchBenchmarked human follicle culture systems with stage-by-stage comparison against natural ovary single-cell atlases$$ $10M – $100M
researchImprinting and aneuploidy assay development so candidate gametes can be screened without a pregnancy$$ $10M – $100M

Sci-fi concepts in reach

Engineered human adaptation to other worldsgatingindirectHuman reproductive cloninggatingdirectGermline trait enhancementdirectIndustrial ectogenesis (hatcheries)directNexus-6 androids (replicants)indirect

Sources